Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease

Table 1 BPK summary data

	WT PN-21 Sham n = 22	WT PN-21 VEH n = 10	WT PN-21 TSV 7.5 n = 10	WT PN-21 TSV 15 n = 10	BPK PN-21 Sham n = 17	BPK PN-21 VEH n = 12	BPK PN-21 TSV 7.5 n = 10	BPK PN-21 TSV 15 n = 14
BW (g)	10.31 ± 0.55	10.76 ± 0.72	10.57 ± 0.80	10.10 ± 0.29	10.46 ± 0.60	10.29 ± 0.45	10.50 ± 0.96	10.11 ± 0.50
TKW (g)	0.15 ± 0.01	0.16 ± 0.02	0.141 ± 0.02	0.13 ± 0.01	2.03 ± 0.28	2.01 ± 0.22	1.59 ± 0.19e	1.21 ± 0.09f,e
KW/BW (%)	1.41 ± 0.10	1.50 ± 0.12	1.33 ± 0.08	1.25 ± 0.09	19.32 ± 1.71	19.57 ± 1.62	15.12 ± 1.1e	11.96 ± 1.22f,e
CI	NA	NA	NA	NA	4.7 ± 0.50	4.8 ± 0.42	3.6 ± 0.52e	2.50 ± 0.35f,e
BUN (mg/dL)	19.25 ± 1.14	21.20 ± 1.99	18.60 ± 2.07	19.40 ± 1.5	108.3 ± 17.8	112 ± 23.3	63.6 ± 20.3e	40.9 ± 13.7d,e
Cr (mg/dL)	0.24 ± 0.05	0.29 ± 0.06	0.24 ± 0.05	0.28 ± 0.06	0.55 ± 0.14	0.58 ± 0.10	0.41 ± 0.1b	0.28 ± 0.07c,e
12 h UCA	1043 ± 35	1065 ± 52	1026 ± 39	1024 ± 27	465 ± 83	460 ± 92	581 ± 67a	786 ± 185.2d,e
BDE	NA	NA	NA	NA	4.8 ± 0.4	4.5 ± 0.5	3.70 ± 0.4b	2.8 ± 0.4d,e

^aP < 0.05,

^bP < 0.01,

^eP < 0.001 vs untreated (Sham) BPK;

^cP < 0.05,

^dP < 0.01,

^fP < 0.001 vs BPK TSV treatment at 7.5. CI: Cystic index; UCA: Urinary concentration ability at 12 h; BDE: Biliary ductal ectasia; KW/BW: Kidney weight to body weight; NA: Not applicable; TKW: Total kidney weight.

Table 2 PCK summary data

	SD PN-90 Sham n = 12	SD PN-90 VEH n = 10	SD PN-90 7.5 mg/kg per day n = 8	SD PN-90 15 mg/kg per day n = 8	PCK PN-90 Sham n = 10	PCK PN-90 VEH n = 12	PCK PN-90 7.5 mg/kg per day n = 10	PCK PN-90 15 mg/kg per day n = 12
BW (g)	375.9 ± 12.1	380 ± 19.46	375 ± 23.23	377 ± 13.31	434 ± 16.6	417.8 ± 21.0	413.4 ± 18.7	406.0 ± 18.5
TKW (g)	3.63 ± 0.46	3.70 ± 0.22	3.71 ± 0.16	3.85 ± 0.32	8.02 ± 0.32	7.54 ± 0.52	6.21 ± 0.44e	5.06 ± 0.43e,f
KW/BW (%)	0.96 ± 0.10	0.97 ± 0.04	0.99.± 0.6	0.91 ± 0.33	1.84 ± 0.09	1.81 ± 0.05	1.50 ± 0.11b	1.18 ± 0.1c,e
CI	NA	NA	NA	NA	7.44 ± 0.8	7.0 ± 0.6	5.3 ± 1.0e	3.8 ± 0.9d,e
BUN (mg/dL)	21.17 ± 1.2	22.40 ± 1.6	23.50 ± 1.7	23.6 ± 1.9	49.2 ± 12.7	48.88 ± 15.3	36.40 ± 4.4b	24.17 ± 8.7c,e
Cr (mg/d)	0.33 ± 0.08	0.34 ± 0.12	0.36 ± 0.05	0.34 ± 0.08	0.67 ± 0.1	0.66 ± 0.12	0.51 ± 0.08b	0.38 ± 0.07c,e
UCA 12 h	2778 ± 159	2983 ± 421	2749 ± 63.1	2712 ± 113	1390 ± 221.9	1448 ± 236	2196 ± 169e	2630 ± 214d,e
LW/BW (%)	4.3 ± 0.47	4.2 ± 0.7	4.13 ± 0.57	4.00 ± 0.65	6.02 ± 0.35	6.08 ± 0.42	5.40 ± 0.21b	4.92 ± 0.27c,e

^aP < 0.05,

^bP < 0.01,

^eP < 0.001 vs untreated (Sham) PCK;

^cP < 0.05,

^dP < 0.01;

^fP < 0.001 vs TSV treatment at 7.5. CI: Cystic index; UCA: Urinary concentration ability at 12 h; LW/BW: Measure of cyst burden; KW/BW: Kidney weight to body weight; TKW: Total kidney weight.